Related Experiment Video
Updated: May 10, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Sildenafil: two decades of benefits or risks?
Luís Antônio B Leoni1, Gerson S Leite, Rogério B Wichi
1Human Movement Laboratory, São Judas Tadeu University, São Paulo/SP, Brazil.
Summary
Sildenafil effectively treats erectile dysfunction (ED) in men, with or without other health conditions. After over 20 years, its benefits clearly outweigh risks, significantly improving quality of life.
Area of Science:
- Pharmacology
- Urology
- Men's Health
Background:
- Sildenafil, a phosphodiesterase type 5 (PDE-5) inhibitor, was patented in 1990 and has been widely available since its patent expiration in 2010.
- Extensive clinical trials have evaluated sildenafil's efficacy and safety for erectile dysfunction (ED), considering various comorbidities.
- Over two decades of market presence necessitate a consensus on its overall risk-benefit profile.
Purpose of the Study:
- To review the scientific consensus on the efficacy and safety of sildenafil for erectile dysfunction (ED).
- To determine if the benefits of sildenafil outweigh its risks after extensive clinical use.
- To assess the impact of sildenafil on the quality of life for men with ED.
Main Methods:
- Systematic review of clinical trials and scientific literature on sildenafil for ED.
- Analysis of safety and efficacy data, including studies with and without comorbidities.
- Evaluation of long-term outcomes and patient-reported quality of life improvements.
Main Results:
- Sildenafil is confirmed as an effective and manageable treatment for ED.
- The drug demonstrates consistent efficacy and safety in patients with and without comorbidities.
- Long-term data support a favorable risk-benefit profile for sildenafil in ED management.
Conclusions:
- Sildenafil is a well-established, effective treatment for erectile dysfunction.
- The benefits of sildenafil significantly outweigh its risks, establishing it as a valuable therapeutic option.
- Sildenafil provides a significant improvement in the quality of life for men experiencing ED.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...